(Q35194482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

title

Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

Karen Brown

series ordinal

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

253-267

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Coronary heart disease mortality and adjuvant tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Tamoxifen-induced severe hypertriglyceridemia and pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Risk of endometrial cancer after tamoxifen treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Uterine sarcoma associated with tamoxifen use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Tamoxifen may increase risk of uterine sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Initiating activity of the anti-estrogen tamoxifen, but not toremifene in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Uterine carcinoma in mice treated neonatally with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

DNA adducts of chemical carcinogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Evaluation of tamoxifen and alpha-hydroxytamoxifen 32P-post-labelled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Understanding the genotoxicity of tamoxifen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Short-term dosing of alpha-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Induction of lacI mutations in Big Blue rats treated with tamoxifen and alpha-hydroxytamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Chemoprevention of breast cancer by tamoxifen: risks and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

The deuterium isotope effect for the alpha-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Identification of the major tamoxifen-DNA adducts in rat liver by mass spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

4-Hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Detection of DNA modifications by the 32P-postlabelling assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.1.3.253

21 January 2018

Identifiers

DOI

10.1517/14740338.1.3.253

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12904141%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference